Session 11: Bone Sarcomas

Chair(s)

• 

  Herbert Ho Fung Loong, MBBS(HK), PDipMDPath(HK), MRCP(UK), FRCP Edin, FHKCP, FHKAM(Medicine) (he/him/his)

  Clinical Associate Professor
  The Chinese University of Hong Kong
  Hong Kong, Hong Kong

Moderator(s)

• aM

  alan Molloy, n/a

  Consultant Orthopaedic Surgeon
  St Vincents University Hospital
  Dublin, Dublin, Ireland
• 

  Sandra Strauss, MD, FRCP, PhD (he/him/his)

  Professor of Medical and TYA Oncology
  University College, London
  London, England, United Kingdom
• 

  Shintaro Iwata, MD (he/him/his)

  Assistant chief
  National Cancer Center Hospital
  Tokyo, Tokyo, Japan

Presentations:

• 10:00 AM – 11:00 AM  

  PRE-TREATMENT CTDNA BURDEN AND GENOMIC FEATURES ARE PROGNOSTIC AMONG PATIENTS WITH METASTATIC EWING SARCOMA TREATED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)
  

  Author: David S. Shulman, MD – Dana-Farber/Boston Children's Cancer and Blood Disorders Center

  Co-Author: Kelly Klega, MS, MLS(ASCP) – Dana-Farber Cancer Institute

  Co-Author: Allen B. Buxton, MS (he/him/his) – Public Health Institute, Children's Oncology Group

  Co-Author: Mohammad Tanhaemami, MS – Dana-Farber Cancer Institute

  Co-Author: Victoria Bainer, n/a – Dana-Farber Cancer Institute

  Co-Author: Carrie Cibulskis, n/a – The Broad Institute

  Co-Author: Richard Gorlick, MD – The University of Texas MD Anderson Cancer Center

  Co-Author: Julia L. Glade Bender, MD (she/her/hers) – Memorial Sloan Kettering Cancer Center

  Co-Author: Damon Reed, MD – Moffitt Cancer Center

  Co-Author: Katherine A. Janeway, MD – Dana-Farber/Boston Children's Cancer and Blood Disorders Center

  Co-Author: Mark Krailo, PhD – University of Southern California

  Co-Author: Steven G. Dubois, MD, MS – Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

  Co-Author: Brian D. Crompton, MD – Dana-Farber/Boston Children's Cancer and Blood Disorders Center
• 10:00 AM – 11:00 AM  

  ARE TREATMENT DELAYS ASSOCIATED WITH A WORSE OUTCOME IN PATIENTS WITH HIGH-GRADE OSTEOSARCOMA? A RETROSPECTIVE ANALYSIS OF DATA FROM THE EURAMOS-1 TRIAL
  

  Author: Dimosthenis Andreou, MD – Medical University of Graz

  Co-Author: Stefanie Hecker-Nolting, MD (she/her/hers) – Olgahospital Stuttgart

  Co-Author: Matthew R. Sydes, CStat (he/him/his) – University College London

  Co-Author: Daniel Baumhoer, MD (he/him/his) – University Hospital Basel

  Co-Author: Odion Binitie, MD – H. Lee Moffitt Cancer Center

  Co-Author: Katherine A. Janeway, MD – Dana-Farber/Boston Children's Cancer and Blood Disorders Center

  Co-Author: Leo Kager, MD – St. Anna Children's Hospital and Children's Cancer Research Institute

  Co-Author: Matthias Kevric, n/a – Olgahospital Stuttgart

  Co-Author: Thomas Kühne, MD – University Children's Hospital Basel

  Co-Author: Andreas Leithner, Prof. MD (he/him/his) – Medical University of Graz

  Co-Author: Damon Reed, MD – Moffitt Cancer Center

  Co-Author: Elyssa Rubin, MD – Children's Hospital of Orange County

  Co-Author: Sigbjørn Smeland, MD – Oslo University Hospital

  Co-Author: Benjamin Sorg, n/a – Olgahospital Stuttgart

  Co-Author: Sandra Strauss, MD, PhD – University Collegue of London (UCL)

  Co-Author: Per-Ulf Tunn, MD – Helios Hospital Berlin-Buch

  Co-Author: Reinhard Windhager, MD – Medical University of Vienna

  Co-Author: Stefan S. Bielack, MD, PhD (he/him/his) – Olgahospital Stuttgart
• 10:00 AM – 11:00 AM  

  SIGNIFICANCE OF EARLY LOCAL PROGRESSION IN NEWLY DIAGNOSED HIGH-GRADE OSTEOSARCOMA- A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP
  

  Author: Odion Binitie, MD – H. Lee Moffitt Cancer Center

  Co-Author: Mark Krailo, PhD – University of Southern California

  Co-Author: Ruxu Han, MS – Children's Oncology Group

  Co-Author: Elyssa Rubin, MD – Children's Hospital of Orange County

  Co-Author: Holcombe Grier, MD – Dana Farber Cancer Institute

  Co-Author: Paul Meyers, MD (he/him/his) – Memorial Sloan Kettering Cancer Center

  Co-Author: Steven G. Dubois, MD, MS – Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

  Co-Author: Damon Reed, MD – Moffitt Cancer Center

  Co-Author: Katherine A. Janeway, MD – Dana-Farber/Boston Children's Cancer and Blood Disorders Center

  Co-Author: Lara Davis, MD (she/her/hers) – OHSU Knight Cancer Institute
• 10:00 AM – 11:00 AM  

  INCIDENCE AND SURVIVAL OF MALIGNANT BONE SARCOMA DIAGNOSED IN ENGLAND BETWEEN 1995 AND 2020; AN ANALYSIS FROM THE NATIONAL CANCER REGISTRATION AND ANALYSIS SERVICE
  

  Author: Reuben Hastings, MSc – NHS England, UCL Cancer Institute

  Co-Author: Andrew Bacon, MSc – NHS England

  Co-Author: Victoria Vinader, PhD – Bone Cancer Research Trust

  Co-Author: Sean McPhail, PhD – National Disease Registration Service, NHS England

  Co-Author: Lizz Paley, MSc (she/her/hers) – NHS England

  Co-Author: Martin G. McCabe, PhD – University of Manchester

  Co-Author: Craig Gerrand, MD, FRCS Ed (Tr and Orth) – Royal National Orthopaedic Hospital

  Co-Author: Sandra J. Strauss, MD PhD FRCP (she/her/hers) – UCL Cancer Institute
• 10:00 AM – 11:00 AM  

  STUDY OF THE SPATIAL HETEROGENEITY OF THE OSTEOSARCOMA MICROENVIRONMENT IN THE RESISTANCE TO TREATMENT BY DIGITAL PATHOLOGY : MECANOBIOLOGICAL APPROACHES
  

  Author: Anne Gomez-Mascard, MD, PhD – Institut Universitaire du Cancer de Toulouse

  Co-Author: Pauline Assemat, PhD – Institut Mécanique des fluides IMFT

  Co-Author: Antony Mancini, PhD – Institut mécanique des fluides IMFT

  Co-Author: Pascal Swider, PhD – Institut Mécanique des fluides IMFT